



November 5, 2013

## **Evoked Pharma Schedules Webcast and Conference Call for Third Quarter 2013 Financial Results**

SAN DIEGO, Nov. 5, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the Third Quarter of 2013 on Wednesday, November 13, 2013, after the close of the market.

Evoked will hold a conference call on Wednesday, November 13, 2013, at 5:00 p.m. EST to discuss the results. The dial-in numbers are 1-877-407-4018 for domestic callers and 1-201-689-8471 for international callers. The conference ID number for both is 13572565. A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at [www.evokedpharma.com](http://www.evokedpharma.com).

After the live webcast, the event will remain archived on Evoked's website for one year. In addition, a telephonic replay of the call will be available until November 27, 2013. The replay dial-in numbers are 1-877-870-5176 for domestic callers and 1-858-384-5517 for international callers. Please use event passcode 13572565.

### **About Evoked Pharma, Inc.**

Evoked Pharma is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. Diabetic gastroparesis is a GI disorder afflicting millions of sufferers worldwide, in which the stomach takes too long to empty its contents resulting in serious digestive system symptoms. Metoclopramide is the only product currently approved in the United States to treat gastroparesis, and is currently available only in oral and intravenous forms. EVK-001 is a novel formulation of this drug, designed to provide systemic delivery of metoclopramide through intranasal administration.

CONTACT: Investor Contact:

The Ruth Group

Stephanie Carrington / David Burke

Tel: 646-536-7017 / 7009

[scarrington@theruthgroup.com](mailto:scarrington@theruthgroup.com)

[dburke@theruthgroup.com](mailto:dburke@theruthgroup.com)

Media Contact:

The Ruth Group

Melanie Sollid-Penton

Tel: 646-536-7023

[msollid@theruthgroup.com](mailto:msollid@theruthgroup.com)

Source: Evoked Pharma

